Jonathan Ledermann

0:05:22

European Cancer Congress 2013 (ECCO-ESMO-ESTRO) Pressbriefing Prof Jonathan Ledermann

0:05:51

Prof Jonathan Ledermann

0:00:58

Dr. Ledermann on Systemic Treatment for Rare Gynecologic Tumors

0:01:14

Dr. Ledermann on the Treatment Landscape for Rare Gynecologic Cancers

0:07:10

Jonathan A Ledermann – Maintenance Treatment for Recurrent Ovarian Carcinoma

0:04:06

The promise of PARP inhibitors and their emerging role in ovarian cancer

0:01:19

Dr. Ledermann on Phase III ARIEL3 Results in Ovarian Cancer

0:01:59

Trametinib: new treatment for recurrent LGSOC

0:01:57

Dr. Ledermann on PARP Inhibitors in Maintenance Therapy for Ovarian Cancer

0:01:42

Phase III Results for Rucaparib in Ovarian Cancer

0:01:11

Dr. Ledermann on the Additive Effects of Olaparib and Bevacizumab in Ovarian Cancer

0:47:41

Ovarian Cancer Australia Symposium 2016 Professor Jonathan Lederman on PARP Inhibitors.

0:05:35

PARP inhibitors (Jonathan A. Ledermann)

0:01:21

Rucaparib May Improve PFS in Patients With Ovarian Cancer

0:02:09

Rucaparib maintenance for recurrent ovarian carcinoma

0:06:22

SGO 2012 - Dr. Ledermann Interview (PARP Inhibitors)

0:03:27

ICON8: Outcome in progression-free survival for weekly-dose paclitaxel in first-line ovarian cancer

0:01:20

Dr. Ledermann on Rationale for ARIEL3 Trial in Ovarian Cancer

0:02:15

Toxicities Associated With Rucaparib for the Treatment of Ovarian Cancer

0:02:40

Update on Study 19 trial of olaparib in serous ovarian cancer

0:02:12

Ovarian cancer: Future outlook, promising trials, new treatments

0:03:07

Rucaparib maintenance and monotherapy for ovarian cancer: trial updates

0:03:09

The promising potential of PARP inhibitors in ovarian cancer

0:01:02

Where can PARP inhibitors be used